Sangamo scraps public offering ‘after evaluating market conditions’

Sangamo Therapeutics has withdrawn its public stock offering, according to an SEC filing Friday morning. The cell and gene therapy biotech was hoping to sell a portion of a $500 million shelf offering, announced last week, to push out its cash runway and fund its clinical programs.